Searched for
G.V. PRASAD
Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...- Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources sayDr Reddy's Laboratories is poised to launch its generic semaglutide injection, potentially named Obeda, in India by March. This move antici...
- Dr. Reddy's eyes Sputnik vaccine exports after domestic struggleLast month India resumed exports of COVID-19 vaccines for the first time since it banned shipments in April in a bid to focus on inoculatin...
- Dr Reddy’s, Merck’s Covid pill partner in India, sees a short-lived boomAnd this is despite Dr Reddy’s, one of India’s largest drugmakers, gearing to export Sputnik shots next year and expecting regulatory nod t...
- Dr. Reddy's open to making Pfizer COVID pill after Merck dealThe new drugs, which unlike vaccines can be used to treat patients once they contract coronavirus infection, are expected to be a huge mark...
- Dr Reddy’s Q2 results: Consolidated PAT rises 30% YoY, beats estimateThe drugmaker reported an 18 per cent on-year rise in consolidated revenues to Rs. 5,763 crore for the reported quarter, which also beat St...
- Dr Reddy’s Q3 results: Net profit at Rs 19.8 crore, sharply lower than Street estimatesThe company’s consolidated revenues grew 12 per cent on year to Rs. 4,930 crore, which was largely in-line with analysts’ estimate of Rs. 4...
- Dr Reddy's subsidiary sells, assigns US rights for 3 brands to Encore DermatologyCEO G V Prasad said the announcement is in line with its renewed strategy to enable us achieve self-sustainability
- Dr Reddy's hires former Teva exec to lead the businessHis knowledge and experience from leading pharmaceutical businesses of scale will be valuable for our future growth,” said G.V. Prasad CEO ...
- Amazing opportunities for start-ups in heatlh care: GV PrasadPrasad said great progress is likely to be achieved in the next 10-15 years in the field of cancer treatment with the evolution of new trea...
- Can't say if the Teva deal is low-value, will take 2 months to get FTC clearance: GV Prasad, Dr Reddy’s LabsPrasad said that the company will bring in some interesting deals in proprietary product areas where the capital leverage is high.
- We will make efforts to get money back from Venezuela: GV Prasad, Dr Reddy'sGV Prasad of Dr Reddy's said that the company will engage with the Venezuela government to get the money back at the official exchange rate.
- Dr Reddy's to invest in startupsDr Reddy's Laboratories (DRL) will be investing in startups besides partnering with external entities for research and innovation.
- Dr Reddy’s chief GV Prasad bemoans bureaucracy in companyDr Reddy’s Labs has not fully utilised its potential and must break the barriers of bureaucracy within the organisation, chairman of the co...
- Ranbaxy saga has opened eyes of companies: GV Prasad, Dr Reddy’s LaboratoriesAs a company, we have always focussed heavily on improving quality systems, training, approach towards regulatory compliance.
- Anji Reddy's absence not to change DRL's direction: AnalystsThe demise of Anji Reddy, the founder-chairman of pharma major Dr Reddy's Laboratories, is not expected to lead to major directional change...
- Anji Reddy's absence not to change DRL's directionThe demise of Anji Reddy, the founder-chairman Dr Reddy's Laboratories, is not expected to lead to major directional changes, market analys...
- InterGlobe Enterprises' Rahul Bhatia wins Ernst & Young Entrepreneur of the Year Award 2011Rahul Bhatia, Group Managing Director, InterGlobe Enterprises, was on Thursday named as the Ernst & Young Entrepreneur of The Year 2011.
- No Indian co is a tier-I pharma player: GV Prasad, Dr Reddy'sIn a candid conversation, Dr Reddy’s Laboratories’ vice-chairman and MD, GV Prasad, talks about the strengths and weaknesses of the domesti...
- Palepu quits company boardDr Reddy's Lab on Tuesday said Krishna G Palepu has resigned as independent director on the company's board. Mr Palepu was also a member of...
Load More
